A groundbreaking treatment developed in Perth, ARG-007, is emerging as a promising neuroprotective drug aimed at minimising brain damage post-concussion. This innovative medication could potentially shield individuals from the debilitating long-term effects of traumatic brain injuries, which currently impact around 69 million people globally each year and rank as a leading cause of death and disability.
Described by Dr. Liz Dallimore as a “one-shot wonder,” ARG-007 is delivered intravenously and functions by penetrating the brain to safeguard neurons from harm caused by head injuries. According to Associate Professor Francis Corrigan from the University of Adelaide, the drug has demonstrated significant efficacy in pre-clinical trials involving ferrets, resulting in reduced brain injury and enhanced motor and memory functions.
Human clinical trials are slated to commence next year across hospitals in Perth and throughout Australia, marking an exciting step forward in the fight against traumatic brain injuries. Furthermore, results from a recent application of ARG-007 on stroke patients in emergency rooms nationwide are anticipated next month.
The aspirations surrounding ARG-007 are vast, with hopes that it will become a staple in ambulances worldwide, ready to deliver critical protection to those at risk of serious brain injury.